AAP
CRBU icon

Arax Advisory Partners’s Caribou Biosciences CRBU Stock Holding History

Arax Advisory Partners’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$137 Buy
78
+13
+20% +$26 ﹤0.01% 5124
2026
Q1 		$116 Buy
65
+4
+7% +$7 ﹤0.01% 3599
2025
Q4 		$97 Sell
61
-445
-88% -$934 ﹤0.01% 3829
2025
Q3 		$1.18K Buy
+506
New +$955 ﹤0.01% 3223

Other funds holding CRBU

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Arax Advisory Partners's CRBU Position: Q2 2026 in Review

Arax Advisory Partners increased its Caribou Biosciences (CRBU) stake by 20% in Q2 2026, buying an estimated $26 and bringing the position to 78 shares worth $137. The position accounts for ﹤0.01% of the portfolio, ranked #5124.

Arax Advisory Partners first reported a position in CRBU in Q3 2025 and has held it in 4 quarters since. The position peaked at $1.18K in Q3 2025. 137 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

  • Arax Advisory Partners held 78 shares of Caribou Biosciences worth $137 as of Q2 2026.
  • Arax Advisory Partners bought 13 Caribou Biosciences shares in Q2 2026, an estimated $26.
  • Caribou Biosciences made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5124 holding.
  • Arax Advisory Partners first reported a position in Caribou Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Arax Advisory Partners's Caribou Biosciences position peaked at $1.18K in Q3 2025.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.